EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Caplacizumab-Enabled Treatment of Immune-Mediated Thrombotic Thrombocytopenic Purpura Without Plasma Exchange: Evidence, Patient Selection, and Practical Considerations

Nabeel Qasem iD, Yousef Al-Asa'd iD, Mohammed Abdulgayoom iD, Awni Alshurafa, Mohamed Yassin

Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32

DOI: 10.1177/10760296261468955 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 03.08.2026. Verfasst von Nabeel Qasem und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Single-Domain Antibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar National Library.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening autoimmune condition driven by severe ADAMTS13 deficiency. Therapeutic plasma exchange (TPE) is the traditional cornerstone of acute therapy, as it clears autoantibodies and replenishes functional ADAMTS13. However, caplacizumab—an anti-von Willebrand factor nanobody that rapidly blocks platelet-von Willebrand factor interactions—has raised the possibility of safely omitting TPE in carefully selected patients.

Objective

To review the biological rationale, current clinical evidence, patient-selection criteria, safety profile, and practical implementation of utilizing caplacizumab for iTTP treatment without relying on plasma exchange.

Methods

A comprehensive narrative review was conducted. It analyzed published case reports, case series, registry data, comparative cohort studies, and guideline-relevant literature focusing on TPE-free or TPE-sparing caplacizumab-based regimens for iTTP.

Results

Evidence has evolved from isolated, necessity-driven cases to robust multicenter comparative data. Caplacizumab-based, TPE-free treatment combined with immunosuppression consistently drives rapid platelet recovery, typically within three to five days. Large comparative cohorts demonstrate that clinical response, exacerbation rates, refractoriness, and mortality are similar to conventional TPE-based therapies. Furthermore, the TPE-free approach offers the benefits of shorter hospital stays and reduced intensive care utilization. However, a subset of patients with inadequate initial platelet responses or complex comorbidities still required rescue TPE.

Conclusion

TPE-free caplacizumab therapy is a promising, highly targeted strategy, though it should not replace standard therapy outside experienced centers. Safe implementation demands confirmed iTTP, clinical stability, immediate caplacizumab availability, rigorous ADAMTS13 monitoring, adequate immunosuppression, and predefined thresholds for rescue TPE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombotic ThrombocytopenicSingle-Domain AntibodiesHumansPlasma ExchangePatient SelectionADAMTS13 Protein

Stichwörter der Autor:innen

ADAMTS13caplacizumabimmune-mediated thrombotic thrombocytopenic purpuraplasma exchange-free treatmentrituximabtherapeutic plasma exchangevon Willebrand factor

Substanzen

caplacizumabSingle-Domain AntibodiesADAMTS13 Protein

Autor:innen und Institutionen

  • Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.

ORCID-Profile: Nabeel Qasem, Yousef Al-Asa'd, Mohammed Abdulgayoom

Förderung

  • Qatar National Library

Zitieren

APA

Qasem, N., Al-Asa'd, Y., Abdulgayoom, M., Alshurafa, A., & Yassin, M. (2026). Caplacizumab-Enabled Treatment of Immune-Mediated Thrombotic Thrombocytopenic Purpura Without Plasma Exchange: Evidence, Patient Selection, and Practical Considerations. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261468955

Vancouver

Qasem N, Al-Asa'd Y, Abdulgayoom M, Alshurafa A, Yassin M. Caplacizumab-Enabled Treatment of Immune-Mediated Thrombotic Thrombocytopenic Purpura Without Plasma Exchange: Evidence, Patient Selection, and Practical Considerations. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261468955

BibTeX
@article{Qasem2026,
  author = {Qasem, Nabeel and Al-Asa'd, Yousef and Abdulgayoom, Mohammed and Alshurafa, Awni and Yassin, Mohamed},
  title = {Caplacizumab-Enabled Treatment of Immune-Mediated Thrombotic Thrombocytopenic Purpura Without Plasma Exchange: Evidence, Patient Selection, and Practical Considerations},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2026},
  volume = {32},
  doi = {10.1177/10760296261468955}
}
Kostenlos starten →